Teliso-V, in the LUMINOSITY trial, was associated with durable responses in c-Met protein-overexpressing non-squamous EGFR-wildtype NSCLC regardless of the level of expression, giving hope for an approved targeted treatment in the near future [58]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.